Abstract 767P
Background
Cisplatin-based concurrent chemoradiation therapy (CCRT) has been increasingly used for local advanced cervical cancer (LACC). However, recurrence is common after cisplatin-based CCRT. Several treatment strategies have been explored to further improve the outcome. We aimed to evaluate the safety and efficacy of anti-PD-1 (Toripalimab, a humanized immunoglobulin G monoclonal antibody against programmed death 1) combined with cisplatin-based concurrent IMRT for locally advanced cervical cancer.
Methods
This is an open-label, nonrandomized, prospective phase Ⅰ/II study in a single arm. Patients with untreated LACC (2018 FIGO stage IB3, IIA –IVA) were enrolled. All patients were treated with CCRT for 56 days including cisplatin (40 mg/m2, Q1W) combined with image-guidance volume modulated Arc therapy (IG-VMAT) to pelvis (50.4Gy in 28 fractions, pelvic and paraortic nodes with simultaneous nodal boost to 59.4 Gy, 28 fractions), and followed by HDR intracavitary (30-36 Gy in 5-6 fractions) brachytherapy. Toripalimab was administered intravenously at 240 mg every 2 week for 4 cycles. The primary endpoint was incidence and severity of acute adverse events up to 3 months of completing treatment. The secondary endpoints were ORR and PFS.
Results
From Sep 2020 to Sep 2022, a total of 30 patients were enrolled. Median age was 58 years [range: 23–71]. The median follow-up duration was 8.5 months [range: 3.2–27.3]. 29 patients (29/30, 96.7%) completed the treatment, 1 patient (1/30, 3.3%) terminated the treatment because of hemophagic syndrome, who with a history of liver fluke disease. ORR was 100.0% (30/30) at 3 months after treatment. Treatment-related grade 3 or 4 adverse events occurred in 80% (24/30) of patients, primarily leukopenia (63.3%), lymphopenia (36.7%), anemia (26.7%), neutropenia (16.7%). The grade 1-2 potentially immune-related adverse events were chromatosis 5 (16.7%), rash 2 (6.7%), pruritus 2 (6.7%), hypothyroidism 2 (6.7%), adrenal insufficiency 2 (6.7%), No treatment-related deaths occurred.
Conclusions
Toripalimab combined with cisplatin-based concurrent IMRT was tolerable and showed promising antitumor activity in patients with LACC, while immunotherapy-related toxicities should be carefully managed.
Clinical trial identification
NCT04368273.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Shanghai Junshi Biomedicine Technology Co., Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
790P - Uniform prospective molecular analysis of endometrial carcinoma: Feasibility, outcomes, and effect on management
Presenter: Bradley Corr
Session: Poster session 11
791P - Development and validation of nomograms to predict survival in patients with high-grade serous ovarian cancer
Presenter: Xiaolian Peng
Session: Poster session 11
792P - Prognostic role of the modeled CA-125 KELIM in early FIGO stage I and II ovarian cancers (OC): A GCIG individual-patient data meta-analysis
Presenter: Pauline Corbaux
Session: Poster session 11
793P - Strong relationships between the CA-125 KELIM score and the tumor biological effects after neo-adjuvant chemotherapy in advanced ovarian cancer patients: CHIVA trial (GINECO)
Presenter: Ana Maria Catana
Session: Poster session 11
794P - Efficacy of gemcitabine (gem) based therapy in ovarian clear cell carcinoma (OCCC)
Presenter: Jerold Loh
Session: Poster session 11
795P - Tolerability and effectiveness of niraparib in long-term responders with platinum-sensitive recurrent ovarian cancer (GEICO-88R study)
Presenter: Juan Cueva Banuelos
Session: Poster session 11
796P - Initial management and long-term outcome of advanced low-grade serous ovarian cancer (LGSOC) exploring role of surgery and maintenance therapy in the French multicentre ESME database
Presenter: Thomas Papazyan
Session: Poster session 11
797P - Impact of consolidation cycles in predicting recurrence in patients treated with EMA-CO for high-risk gestational trophoblastic neoplasia
Presenter: Antoine DELEUZE
Session: Poster session 11
798P - Survival analysis of non-metastatic gestational choriocarcinoma (NMGCC) patients treated with chemotherapy
Presenter: Sakhr Alshwayyat
Session: Poster session 11